Literature DB >> 3674537

Measles (rubeola) infection in a hospital setting.

N M Watkins1, R P Smith, D L St Germain, D N MacKay.   

Abstract

Although acquisition of measles infection in medical facilities is well documented, hospital outbreaks have been rare. During a recent community measles epidemic, one patient and four employees of the Mary Hitchcock Memorial Hospital developed the disease. Two of the employees were born before 1956, the year recommended by the Centers for Disease Control as an appropriate cutoff year for routine measles vaccination. Screening of 456 hospital employees for measles immunity demonstrated a 5% incidence of susceptibility in 135 individuals born between 1950 and 1956. This experience demonstrates the significant potential for the spread of a community measles outbreak into the hospital setting. Because of the high transmissibility of this disease and its potentially serious consequences in hospitalized patients, we suggest that all hospital employees born after 1950 who have significant patient contact should have documented immunity against measles.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674537     DOI: 10.1016/0196-6553(87)90096-4

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  3 in total

1.  GUIDELINES FOR THE PREVENTION AND CONTROL OF MEASLES OUTBREAKS IN CANADA: An Advisory Committee Statement (ACS) Measles and Rubella Elimination Working Group (MREWG).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2013-10-30

2.  Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.

Authors:  T R Coté; D Sivertson; J M Horan; M L Lindegren; D M Dwyer
Journal:  Public Health Rep       Date:  1993 Jul-Aug       Impact factor: 2.792

Review 3.  A global perspective of vaccination of healthcare personnel against measles: systematic review.

Authors:  Amy Parker Fiebelkorn; Jane F Seward; Walter A Orenstein
Journal:  Vaccine       Date:  2013-11-24       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.